Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2023-12-19 DOI:10.1038/s41571-023-00854-y

Pier Paolo M. Berton Giachetti, Giuseppe Curigliano

引用次数: 0

Abstract

Recent results from the phase III PHILA trial demonstrate a benefit in terms of progression-free survival derived from the addition of pyrotinib to first-line chemotherapy plus trastuzumab in patients with metastatic HER2-positive breast cancer. Dual HER2 blockade with pyrotinib and trastuzumab is an effective therapeutic strategy but might increase the risk of gastrointestinal toxicity; therefore, the risk-to-benefit ratio should be carefully evaluated.

查看原文本刊更多论文

派罗替尼联合一线曲妥珠单抗和多西他赛治疗HER2阳性转移性乳腺癌患者：一种新的治疗选择？

PHILA III 期试验的最新结果表明，在转移性 HER2 阳性乳腺癌患者一线化疗加曲妥珠单抗的基础上加用派罗替尼，可提高无进展生存期。使用派罗替尼和曲妥珠单抗进行HER2双重阻断是一种有效的治疗策略，但可能会增加胃肠道毒性的风险；因此，应仔细评估其风险收益比。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.